AbbVie reports ‘positive’ results from Phase 3b/4 SELECT-SWITCH study

AbbVie (ABBV) announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib 15 mg, once daily, compared to adalimumab 40 mg, every other week, in adult patients with moderate to severe rheumatoid arthritis on a stable background of methotrexate who had an inadequate response or intolerance to a TNF inhibitor other than adalimumab. This study achieved the primary endpoint and the majority of ranked secondary endpoints at week 12 with no new safety risks identified. A significantly higher proportion of patients who received upadacitinib achieved low disease activity and remission compared to adalimumab at week 12. Upadacitinib also demonstrated superiority versus adalimumab for additional ranked secondary endpoints measured at week 12. 43.3% of patients receiving upadacitinib achieved DAS28-CRPless than or equal to3.2 compared to 22.4% of patients on adalimumab. 28.4% of patients receiving upadacitinib achieved DAS28-CRPless than2.6 compared to 14.5% of patients on adalimumab.